These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 16732904

  • 21. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN, Chauhan R, Das BC, Sarin SK.
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [Abstract] [Full Text] [Related]

  • 22. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.
    Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Takagi K, Kobayashi M, Ikeda K, Kumada H.
    J Gastroenterol; 2004 Jan; 39(1):34-40. PubMed ID: 14767732
    [Abstract] [Full Text] [Related]

  • 23. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.
    Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B.
    Hepatology; 2004 Jan; 39(1):64-73. PubMed ID: 14752824
    [Abstract] [Full Text] [Related]

  • 24. [Quasispecies and mutation of hepatitis B virus polymerase gene in lamivudine- treated patients].
    Huang YP, Wang YM, Lan L, Fan Y.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):235-8. PubMed ID: 12716526
    [Abstract] [Full Text] [Related]

  • 25. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH.
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [Abstract] [Full Text] [Related]

  • 26. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
    Hsu CW, Yeh CT, Chang ML, Liaw YF.
    Gastroenterology; 2007 Feb; 132(2):543-50. PubMed ID: 17258721
    [Abstract] [Full Text] [Related]

  • 27. [Detection of YMDD mutations in hepatitis B virus DNA with the use of allele specific polymerase chain reaction].
    Pichkovskaia VA, Fevraleva IS, Ibragimova MM, Solov'eva TI, Drel' PE, Sudarikov AB.
    Mol Gen Mikrobiol Virusol; 2004 Feb; (1):27-9. PubMed ID: 15025001
    [Abstract] [Full Text] [Related]

  • 28. [Relationship between B virus hepatitis genotypes and therapeutic efficacy in early treatment for chronic hepatitis B by using lamivudine].
    Song SJ, Zhuang H, Yan J, Wei HS, He ZP, Song C, Dong QM, Xiao YP.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2005 May; 39(3):203-5. PubMed ID: 15938857
    [Abstract] [Full Text] [Related]

  • 29. A PCR-RFLP based protocol for the detection of hepatitis B virus variants in some lamivudine-untreated chronic hepatitis B virus carriers in Pakistan.
    Tauseef I, Iqbal F, Rehman W, Ali M, Qureshi JA, Aslam MA.
    Pak J Pharm Sci; 2012 Apr; 25(2):349-52. PubMed ID: 22459460
    [Abstract] [Full Text] [Related]

  • 30. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
    Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M.
    Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
    [Abstract] [Full Text] [Related]

  • 31. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
    Yeh CT, Chien RN, Chu CM, Liaw YF.
    Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
    [Abstract] [Full Text] [Related]

  • 32. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
    Marrone A, Zampino R, Karayannis P, Cirillo G, Cesaro G, Guerrera B, Ricciotti R, del Giudice EM, Utili R, Adinolfi LE, Ruggiero G.
    Aliment Pharmacol Ther; 2005 Oct 15; 22(8):707-14. PubMed ID: 16197491
    [Abstract] [Full Text] [Related]

  • 33. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
    Woo HY, Park H, Kim BI, Jeon WK, Cho YK, Kim YJ.
    Antivir Ther; 2007 Oct 15; 12(1):7-13. PubMed ID: 17503742
    [Abstract] [Full Text] [Related]

  • 34. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF.
    J Viral Hepat; 2007 Nov 15; 14(11):767-74. PubMed ID: 17927612
    [Abstract] [Full Text] [Related]

  • 35. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.
    Li MW, Hou W, Wo JE, Liu KZ.
    J Zhejiang Univ Sci B; 2005 Jul 15; 6(7):664-7. PubMed ID: 15973769
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW, Liu CJ, Lai MY, Lee PH, Tsai MK, Wang SS, Lai MK, Kao JH.
    Clin Ther; 2006 Sep 15; 28(9):1327-34. PubMed ID: 17062306
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Mutation patterns in the RT region of hepatitis B virus P gene in patients treated with nucleoside/nucleotide analogs].
    DENG J, ZHANG DH, YU DM, CHEN L, ZHANG XX.
    Zhonghua Gan Zang Bing Za Zhi; 2009 May 15; 17(5):342-5. PubMed ID: 19497198
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.